The role of lamotrigine in the management of bipolar disorder

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 4, 2007, Pages 463-474

  Ng, Felicity ^a   Hallam, Karen ^a   Lucas, Nellie ^b   Berk, Michael ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ORYGEN RESEARCH CENTRE   (Australia)

Author keywords

Bipolar depression; Bipolar disorder; Clinical trials; Efficacy; Lamotrigine

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; GABAPENTIN; INOSITOL; LAMOTRIGINE; LITHIUM SALT; MOOD STABILIZER; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RIFAMPICIN; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE;

ADJUVANT THERAPY; ALCOHOLISM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BORDERLINE STATE; CLINICAL TRIAL; COCAINE DEPENDENCE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGENITAL MALFORMATION; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EVIDENCE BASED MEDICINE; GLUCURONIDATION; HALLUCINATION; HUMAN; HYPOMANIA; HYPONATREMIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MANIA; MAXIMUM TOLERATED DOSE; MEDLINE; MONOTHERAPY; NEUROPROTECTION; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PLASMA PROTEIN BINDING; PRENATAL DRUG EXPOSURE; QUALITY OF LIFE; RAPID CYCLING BIPOLAR DISORDER; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TERATOGENICITY; TIC; TOXIC EPIDERMAL NECROLYSIS;

EID: 35648962950     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. American Psychiatric Association. 2002. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry, 159:1-50.
2. Angst J, Sellaro R. 2000. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry, 48:445-57.
3. Baldessarini RJ, Tondo L, Hennen J. 2003. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry, 64(Suppl 5):44-52.
4. Barbosa L, Berk M, Vorster M. 2003. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry, 64:403-7.
5. Bauer MS, Mitchner L. 2004. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry, 161:3-18.
6. Berk M, Ichim L, Brook S. 1999. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol, 14:339-43.
7. Berk M, Plein H, Belsham B. 2000. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci, 66:2427-32.
8. Besag FM, Ng GY, Pool F. 2000. Successful re-introduction of lamotrigine after initial rash. Seizure, 9:282-6.
9. Blum D, Meador K, Biton V, et al. 2006. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology, 67:400-6.
10. Bourin M, Masse F, Hascoet M. 2005. Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test. J Psychiatry Neurosci, 30:275-82.
11. Bowden CL, Asnis GM, Ginsberg LD, et al. 2004. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf, 27:173-84.
12. Bowden CL, Calabrese JR, Sachs G, et al. 2003. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry, 60:392-400.
13. Bowden CL, Karren NU. 2006. Anticonvulsants in bipolar disorder. Aust N Z J Psychiatry, 40:386-93.
14. Bowden CL, Singh V. 2005. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand, Suppl: 13-20.
15. Brown E, Nejtak V, Perantie D, et al. 2003. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry, 64:197-201.
16. Brown E, Perantie D, Dhanam N, et al. 2006. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. Journal of Affective Disorders, 93:219-2.
17. Brown EB, McElroy SL, Keck PE Jr, et al. 2006. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry, 67:1025-33.
18. Calabrese JR, Bowden CL, McElroy SL, et al. 1999. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry, 156:1019-23.
19. Calabrese JR, Bowden CL, Sachs G, et al. 2003. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry, 64:1013-24.
20. Calabrese JR, Bowden CL, Sachs GS, et al. 1999. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry, 60:79-8.
21. Calabrese JR, Kasper S, Johnson G, et al. 2004. International consensus group on bipolar I depression treatment guidelines. J Clin Psychiatry, 65:571-9.
22. Calabrese JR, Keck PE Jr, Macfadden W, et al. 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry, 162:1351-60.
23. Calabrese JR, Suppes T, Bowden CL, et al. 2000. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry, 61:841-50.
24. Calabrese JR, Woyshville MJ. 1995. Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Ann Clin Psychiatry, 7:103-12.
25. Chosidow O, Stern R, Wintroub B. 2005. Part 2. cardinal manifestations and presentations of diseases. Section 9. Alterations in the skin. Chapter 50. Cutaneous drug reactions. Harrison's principles of internal medicine 16th.
26. Cunnington M, Tennis P. 2005. Lamotrigine and the risk of malformations in pregnancy. Neurology, 64:955-60.
27. Daban C, Martinez-Aran A, Torrent C, et al. 2006. Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. J Clin Psychopharmacol, 26:178-81.
28. Data on file, Lamictal, RM1997/00712/00, Study Synopsis of SCAA2010 (603), 1999.
29. Data on file, Lamictal, RM2002/00129/00, Clinical Study Report for SCA40910, 2002, p 2-4, 58-59.
30. Data on file, Lamictal, RM2004/00533/00, Study Synopsis of SCA100223, 2006.
31. Ebert U, Thong NQ, Oertel R, et al. 2000. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol, 56:299-304.
32. Fagiolini A, Frank E, Scott JA, et al. 2005. Metabolic syndrome in bipolar disorder: findings from the bipolar disorder center for pennsylvanians. Bipolar Disord, 7:424-30.
33. French LE, Trent JT, Kerdel FA. 2006. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol, 6:543-9.
34. Frye MA, Ketter TA, Kimbrell TA, et al. 2000. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol, 20:607-14.
35. Ginsberg LD. 2006. Efficacy and safety of lamotrigine for adults with bipolar disorder in a private practice setting. CNS Spectr, 11:376-82.
36. Goldberg JF, Truman CJ. 2003. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord, 5:407-20.
37. Goodwin GM, Bowden CL, Calabrese JR, et al. 2004. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry, 65:432-41.
38. Greil W, Kleindienst N, Erazo N, et al. 1998. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol, 18:455-60.
39. Grunze H, Kasper S, Goodwin G, et al. 2002. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry, 3:115-24.
40. Grunze H, Kasper S, Goodwin G, et al. 2004. The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry, 5:120-35.
41. Hachad H, Ragueneau-Majlessi I, Levy RH. 2002. New antiepileptic drugs: review on drug interactions. Ther Drug Monit, 24:91-103.
42. Hahn CG, Gyulai L, Baldassano CF, et al. 2004. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry, 65:791-804.
43. Ichim L, Berk M, Brook S. 2000. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry, 12:5-10.
44. Judd LL, Akiskal HS, Schettler PJ, et al. 2003. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry, 60:261-9.
45. Judd LL, Akiskal HS, Schettler PJ, et al. 2002. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry, 59:530-7.
46. Kaufman KR, Gerner R. 1998. Lamotrigine toxicity secondary to sertraline. Seizure, 7:163-5.
47. Keck PE Jr, Marcus R, Tourkodimitris S, et al. 2003. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry, 160:1651-8.
48. Keck PE Jr, McElroy SL. 2002. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry, 63(Suppl 4):3-1.
49. Keck PE Jr, McElroy SL, Strakowski SM, et al. 1997. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull, 33:87-91.
50. Ketter TA. 2004. Sustained remission/euthymia with quetiapine monotherapy for bipolar manic states. Collegium internationale neuropsychopharmacologicum, Paris, France.
51. Ketter TA, Calabrese JR. 2002. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry, 63:146-51.
52. Ketter TA, Greist JH, Graham JA, et al. 2006. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial. J Clin Psychiatry, 67:400-6.
53. Ketter TA, Manji HK, Post RM. 2003. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol, 23:484-95.
54. Khan A, Ginsberg LD, Asnis GM, et al. 2004. Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. J Clin Psychiatry, 65:1483-90.
55. Kraepelin E. 2002. Manic depressive insanity and paranoia. Barclay M, translator. Bristol: Thoemmes Press. Reprint of 1921 edition.
56. Liporace J, Kao A, D'Abreu A. 2004. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav, 5:102-5.
57. Maj M. 2003. The effect of lithium in bipolar disorder: a review of recent research evidence. Bipolar Disord, 5:180-8.
58. Manfredi G, Pacchiarotti I, Kotzalidis GD, et al. 2004. Successful rechallenge with slowly titrated lamotrigine after rash. Bipolar Disord, 6:338-9.
59. McElroy SL, Zarate CA, Cookson J, et al. 2004. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry, 65:204-10.
60. McIntyre R, Mancini D, Fulton K. 2004. Double-blind acute depression study comparing venlafaxine XR and lamotrigine when added to a mood stabilizer in the treatment of bipolar depression. Int J Neuropsychopharmacol, 7(Suppl 2):S154.
61. Messenheimer J, Mullens EL, Giorgi L, et al. 1998. Safety review of adult clinical trial experience with lamotrigine. Drug Saf, 18:281-96.
62. Messenheimer JA. 1998. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci, 25:S14-18.
63. Mewasingh L, Aylett S, Kirkham F, et al. 2000. Hyponatraemia associated with lamotrigine in cranial diabetes insipidus. Lancet, 356:656.
64. Mitchell PB, Slade T, Andrews G. 2004. Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey. Psychol Med, 34:777-85.
65. Morrow J, Russell A, Guthrie E, et al. 2006. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry, 77:193-8.
66. Narasimhan M, Buckley PF. 2006. Predictors of response to pharmacological treatments in bipolar disorder. Clinical Approaches in Bipolar Disorders, 5:36-44.
67. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. 2006. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry, 163:210-16.
68. Obrocea G, Dunn R, Frye MA, et al. 2002. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry, 51:253-60.
69. Ohman I, Vitols S, Tomson T. 2000. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia, 41:709-13.
70. Paykel ES, Abbott R, Morriss R, et al. 2006. Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry, 189:118-23.
71. Peck AW. 1991. Clinical pharmacology of lamotrigine. Epilepsia, 32(Suppl 2):S9-12.
72. Perucca E. 2006. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol, 61:246-55.
73. Preston G, Marchant B, Reimherr F, et al. 2004. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. Journal of Affective Disorders, 79:297-303.
74. Raskin S, Teitelbaum A, Zislin J, et al. 2006. Adjunctive lamotrigine as a possible mania inducer in bipolar patients. Am J Psychiatry, 163:159-60.
75. Rihmer Z, Kiss K. 2002. Bipolar disorders and suicidal behaviour. Bipolar Disord, 4(Suppl 1):21-5.
76. Robinson LJ, Thompson JM, Gallagher P, et al. 2006. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord, 93:105-15.
77. Rubio G, Lopez-Munoz F, Alamo C. 2006. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord, 8:289-93.
78. Sabers A, Buchholt JM, Uldall P, et al. 2001. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res, 47:151-4.
79. Sachs G, Bowden C, Calabrese JR, et al. 2006. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord, 8:175-81.
80. Schaffer A, Zuker P, Levitt A. 2006. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. 159th Annual Meeting, American Psychiatrifc Association., Toronto, Ontario, Canada.
81. Seemuller F, Dehning S, Grunze H, et al. 2006. Tourette's symptoms provoked by lamotrigine in a bipolar patient. Am J Psychiatry, 163:159.
82. Segal J, Berk M, Brooks S. 1998. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clinical Neuropsychopharmacology, 21:176-80.
83. Sidhu J, Job S, Singh S, et al. 2006. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol, 61:191-9.
84. Simon GE, Von Korff M, Saunders K, et al. 2006. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry, 63:824-30.
85. Sinz MW, Remmel RP. 1991. Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metab Dispos, 19:149-53.
86. Smith ME, Gevins A, McEvoy LK, et al. 2006. Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia, 47:695-703.
87. Sotero de Menezes MA, Rho JM, Murphy P, et al. 2000. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia, 41:862-7.
88. Suppes T, Dennehy EB, Hirschfeld RM, et al. 2005. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry, 66:870-86.
89. Tavernor SJ, Wong IC, Newton R, et al. 1995. Rechallenge with lamotrigine after initial rash. Seizure, 4:67-71.
90. The Royal Australian and New Zealand College of Psychiatrists. 2004. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry, 38:280-305.
91. Tohen M, Vieta E, Calabrese J, et al. 2003. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry, 60:1079-8.
92. Tomson T, Ohman I, Vitols S. 1997. Lamotrigine in pregnancy and lactation: a case report. Epilepsia, 38:1039-41.
93. Tondo L, Baldessarini RJ, Hennen J, et al. 1998. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry, 155:638-45.
94. Trojnar MK, Malek R, Chroscinska M, et al. 2002. Neuroprotective effects of antiepileptic drugs. Pol J Pharmacol, 54:557-6.
95. Uher R, Jones HM. 2006. Hallucinations during lamotrigine treatment of bipolar disorder. Am J Psychiatry, 163:749-50.
96. Walden J, Schaerer L, Schloesser S, et al. 2000. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar Disord, 2:336-9.
97. Weissman MM, Bland RC, Canino GJ, et al. 1996. Cross-national epidemiology of major depression and bipolar disorder. Jama, 276:293-9.
98. Werz MA, Schoenberg MR, Meador KJ, et al. 2006. Subjective preference for lamotrigine or topiramate in healthy volunteers: relationship to cognitive and behavioral functioning. Epilepsy Behav, 8:181-91.
99. Wiard RP, Dickerson MC, Beek O, et al. 1995. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke, 26:466-72.
100. Yatham LN. 2004. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry, 65(Suppl 10):28-35.
101. Yatham LN, Kennedy SH, O'Donovan C, et al. 2005. Canadian network for mood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord, 7(Suppl 3):5-69.